Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 75/100

Failure Rate

25.0%

1 terminated/withdrawn out of 4 trials

Success Rate

75.0%

-11.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

33%

1 of 3 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 2
3(75.0%)
Phase 1
1(25.0%)
4Total
Phase 2(3)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT03919162Phase 2Terminated

A Trial to Evaluate the Efficacy and Safety of PQ912 in Patients With Early AD

Role: lead

NCT04498650Phase 2Completed

A Study to Evaluate Safety and Tolerability of Different Doses and Efficacy of PQ912 in Subjects With MCI and Mild AD

Role: lead

NCT02389413Phase 2Completed

Safety and Tolerability of PQ912 in Subjects With Early Alzheimer's Disease

Role: lead

NCT02190708Phase 1Completed

Effects of PQ912 on the Pharmacokinetics of Midazolam and Omeprazole

Role: lead

All 4 trials loaded